Routine once-weekly darbepoetin alfa administration is cost-effective in lung cancer patients with chemotherapy-induced anemia: A Markov analysis

Lung Cancer

Volumn 51, Issue 3, 2006, Pages 369-376

  Borget, Isabelle ^a   Tilleul, Patrick ^a   Baud, Mariette ^a   Joly, Anne Christine ^a   Daguenel, Anne ^a   Chouaid, Christos ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Anemia; Erythropoetin; Lung cancer; Medico economic analysis; Transfusion

Indexed keywords

CISPLATIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; COSTS AND COST ANALYSIS; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MARKOV CHAINS; MIDDLE AGED;

EID: 33144489372     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.10.024     Document Type: Article

References (33)

1. S. Chang, S.R. Long, L. Kutikova, L. Bowman, D. Finley, and W.H. Crown Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000 J Clin Oncol 22 2004 3524 3530
2. C. Chouaid, L. Molinier, C. Combescure, J.P. Daures, B. Housset, and A. Vergnenegre Economics of the clinical management of lung cancer in France: an analysis using a Markov model Br J Cancer 90 2004 397 402
3. K.J. Dedes, T.D. Szucs, S. Bodis, M. Joerger, A. Lowy, and E.W. Russi Management and costs of treating lung cancer patients in a university hospital Pharmacoeconomics 22 2004 435 444
4. J. Crawford, D. Cella, C.S. Cleeland, P.Y. Cremieux, G.D. Demetri, and B.J. Sarokhan Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy Cancer 95 2002 888 895
5. J. Glaspy, R. Bukowski, D. Steinberg, C. Taylor, S. Tchekmedyian, and S. Vadhan-Raj Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group J Clin Oncol 15 1997 1218 1234
6. J. Vansteenkiste Aranesp 980297 Study Group. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy J Natl Cancer Inst 94 2002 1211 1220
7. J.A. Glaspy, J.S. Jadeja, G. Justice, A. Fleishman, G. Rossi, and A.B. Colowick A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease Cancer 97 2003 1312 1320
8. J.A. Glaspy Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency Oncology (Huntingt) 16 2002 71 77
9. A. Ortega, G. Dranitsaris, and A.L. Puodziunas What are cancer patients willing to pay for prophylactic epoetin alfa? A cost-benefit analysis Cancer 83 1998 2588 2596
10. G. Barosi, M. Marchetti, and N.L. Liberato Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia Br J Cancer 78 1998 781 787
11. R. Sheffield, S.D. Sullivan, E. Saltiel, and L. Nishimura Cost comparison of recombinant human erythropoietin and blood transfusion in cancer chemotherapy-induced anemia Ann Pharmacother 31 1997 15 22
12. P.Y. Cremieux, S.N. Finkelstein, E.R. Berndt, J. Crawford, and M.B. Slavin Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia Pharmacoeconomics 16 1999 459 472
13. A.M. Meadowcroft, C.J. Gilbert, D. Maravich-May, and S.L. Hayward Cost of managing anemia with and without prophylactic epoetin alfa therapy in breast cancer patients receiving combination chemotherapy Am J Health Syst Pharm 55 1998 1898 1902
14. M. Marchetti, and G. Barosi Clinical and economic impact of epoetins in cancer care Pharmacoeconomics 22 2004 1029 1045
15. F.A. Sonnenberg, and J.R. Beck Markov models in medical decision making: a practical guide Med Decis Making 13 1993 322 338
16. A.S. Desky, and I.G. Naglie A clinician's guide to cost-effectiveness analysis Ann Intern Med 113 1990 147 154
17. UCANSS: Nomenclature Générale des Actes Professionnels des Médecins, Chirurgiens-dentistes, Sages-femmes et Auxiliaires médicaux. Nomenclature des actes de biologie médicale, vol. 1, CNAMTS ed.; 2003.
18. G.D. Demetri, M. Kris, J. Wade, L. Degos, and D. Cella Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group J Clin Oncol 16 1998 3412 3425
19. J.L. Gabrilove, C.S. Cleeland, R.B. Livingston, B. Sarokhan, E. Winer, and L.H. Einhorn Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing J Clin Oncol 19 2001 2875 2882
20. T.J. Littlewood The impact of hemoglobin levels on treatment outcomes in patients with cancer Semin Oncol 28 2001 49 53
21. G.V. Scagliotti, and S. Novello Role of erythropoietin in the treatment of lung cancer associated anaemia Lung Cancer 34 2001 S91 S94
22. S. Ramalingam, and C.P. Belani Meaningful survival in lung cancer patients Semin Oncol 29 2002 125 131
23. B. Coiffier, J.P. Guastalla, E. Pujade-Lauraine, and P. Bastit Anemia Study Group. Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey Eur J Cancer 37 2001 1617 1623
24. J.E. Groopman, and L.M. Itri Chemotherapy-induced anemia in adults: incidence and treatment J Natl Cancer Inst 91 1999 1616 1634
25. F.A. Shepherd, J. Dancey, R. Ramlau, K. Mattson, R. Gralla, and M. O'Rourke Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
26. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennet C, et al. Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev 2004;3:CD003407.
27. B. Mirtsching, V. Charu, S. Vadhan-Raj, A.B. Colowick, G. Rossi, and D. Tomita Every-2-week darbepoetin alfa is comparable to rHuEPO in treating chemotherapy-induced anemia. Results of a combined analysis Oncology (Huntingt) 16 2002 31 36
28. D. Kotasek Aranesp 980291 Study Group. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study Eur J Cancer 39 2003 2026 2034
29. W.A. Thames, S.L. Smith, A.C. Scheifele, B. Yao, S.A. Giffin, and J.L. Alley Evaluation of the US Oncology Network's recommended guidelines for therapeutic substitution with darbepoetin alfa 200 microg every 2 weeks in both naive patients and patients switched from epoetin alfa Pharmacotherapy 24 2004 313 323
30. L. Fallowfield Epoetin Alfa Study Group. Multivariate regression analyses of data from a randomised, double-blind, placebo-controlled study confirm quality of life benefit of epoetin alfa in patients receiving non-platinum chemotherapy Br J Cancer 87 2002 1341 1353
31. M. Lind, C. Vernon, D. Cruickshank, P. Wilkinson, T. Littlewood, and N. Stuart The level of haemoglobin in anaemic cancer patients correlates positively with quality of life Br J Cancer 86 2002 1243 1249
32. C. Chouaid, L. Bassinet, C. Fuhrman, I. Monnet, and B. Housset Routine use of granulocyte colony-stimulating factor is not cost-effective and does not increase patient comfort in the treatment of small-cell lung cancer: an analysis using a Markov model J Clin Oncol 16 1998 2700 2707
33. G.L. Plosker, and R.J. Milne Ondansetron: a pharmacoeconomic and quality-of-life evaluation of its antiemetic activity in patients receiving cancer chemotherapy Pharmacoeconomics 2 1992 285 304